MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [21] Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply
    Gebski, Val
    Huttunen, Teppo
    Joensuu, Heikki
    JAMA ONCOLOGY, 2019, 5 (01) : 118 - 118
  • [22] A novel circular RNA confers trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer through regulating ferroptosis
    Wang, Shengting
    Wang, Yufang
    Li, Qian
    Li, Xiaoming
    Feng, Xinghua
    ENVIRONMENTAL TOXICOLOGY, 2022, 37 (07) : 1597 - 1607
  • [23] Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load
    Munnink, Thijs H. Oude
    Dijkers, Eli C.
    Netters, Sabine J.
    Lub-de Hooge, Marjolijn N.
    Brouwers, Adrienne H.
    Haasjes, Janny G.
    Schroder, Carolina P.
    de Vries, Elisabeth G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : E355 - E356
  • [24] Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
    Yu, Tosol
    Cho, Bong Jun
    Choi, Eun Jung
    Park, Ji Min
    Kim, Dan Hyo
    Kim, In Ah
    ONCOTARGET, 2016, 7 (48) : 79075 - 79086
  • [25] Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model
    Harada, Suguru
    Yanagisawa, Mieko
    Kaneko, Saori
    Yorozu, Keigo
    Yamamoto, Kaname
    Moriya, Yoichiro
    Harada, Naoki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 987 - 994
  • [26] Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis
    Yoshihara, Kazutaka
    Kobayashi, Yoshimasa
    Endo, Seiko
    Fukae, Masato
    Hennig, Stefanie
    Kastrissios, Helen
    Kamiyama, Emi
    Garimella, Tushar
    Abutarif, Malaz
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (11): : 1232 - 1243
  • [27] Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Bum Jun
    Kim, Hyunki
    Yun, Un-Jung
    Che, Jingmin
    Park, Sejung
    Kim, Tae Soo
    Kwon, Woo Sun
    Park, Juin
    Cho, Sang Woo
    Nam, Chung Mo
    Chung, Hyun Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (27) : 4394 - +
  • [28] Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Albin, Nicolas
    Monard, Adrien
    Desplas, David
    Zureik, Mahmoud
    Haddy, Nadia
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (12)
  • [29] Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Xie, Jindong
    Zou, Yutian
    Gao, Ting
    Xie, Liming
    Tan, Duxun
    Xie, Xiaoming
    CANCER CONTROL, 2022, 29
  • [30] Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
    LoRusso, Patricia M.
    Weiss, Denise
    Guardino, Ellie
    Girish, Sandhya
    Sliwkowski, Mark X.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6437 - 6447